Failure to ensure equitable, sustainable access to vaccines has public health and financial consequences, including for Pfizer and its stockholders. Pfizer faces significant reputational and business risks for failing to ensure equitable access to its COVID-19 vaccine. Pfizer could face increased regulatory risks during and after the COVID-19 pandemic due to its failure to sustain adequate supply. In 2023, access to lifesaving COVID-19 vaccines remains highly inequitable, in part due to inequitable initial distributions by pharmaceutical companies. Investors should understand how these issues have been considered in the company’s management of its high-revenue COVID-19 vaccine.

Source: Los Angeles Times April 12, 2023 13:29 UTC